SALEM, Mass. — Commonwealth Diagnostics International (CDI) is excited to share the benefits of our new in-network status with CareFirst BlueCross BlueShield and CareFirst BlueChoice, the most extensive not-for-profit health plan in the Mid-Atlantic. This partnership, covering over 3.5 million individuals and groups in Maryland, the Washington D.C. metropolitan area, and parts of Virginia, significantly enhances access to CDI’s cutting-edge hydrogen and methane breath testing for adult and pediatric GI patients.
Craig Strasnick, President & CEO of CDI, stated, “We are excited to join forces with CareFirst, enhancing the accessibility and affordability of our breath testing services. This collaboration underscores our commitment to providing high-quality, non-invasive diagnostic solutions for functional GI disorders, ensuring that more patients receive the accurate diagnoses and personalized care they need.”
This announcement marks another milestone in CDI’s ongoing efforts to expand our network of commercial providers. Earlier this year, CDI was approved as an in-network provider with Blue Cross and Blue Shield of Illinois, further broadening our reach. Additionally, CDI accepts all Medicare, Medicare Advantage, and Tricare government-managed health insurance plans, making our breath tests fully covered by Medicare with no balance billing. Our commitment to reducing out-of-pocket costs for patients remains a top priority.
CDI’s breath tests are now more accessible to a broader population, offering providers an invaluable tool to diagnose conditions like Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methanogen Overgrowth (IMO), and fructose, sucrose, and lactose carbohydrate malabsorption disorders.
For a complete list of in-network providers, visit commdx.com/insurance.
About Commonwealth Diagnostics International, Inc. (CDI):
Commonwealth Diagnostics International, Inc. (CDI) is an innovative GI health company providing industry-leading diagnostic tests and tools to help physicians identify and diagnose familiar sources of digestive distress and functional GI ailments for adults and pediatric patients. Focused on their patient-centric principles, their cost-effective portfolio of diagnostic products results in expedited treatment, better patient outcomes, and robust cost savings for the healthcare delivery system. Their expansive portfolio includes non-invasive at-home breath testing kits for Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methane Overgrowth (IMO), and carbohydrate malabsorption disorders, as well as technology solutions, including MyGI Gateway, a cutting-edge provider portal for enhanced patient care, and MyGI Health, a cloud-based platform that enables patients to monitor, manage and understand their GI-related symptoms. CDI manufactures its clinically validated, FDA-registered and CE marked breath test kits according to ISO 13485 standards and perform all diagnostics in our state-of-the-art, CLIA-certified lab utilizing proprietary diagnostic technologies. For more information, visit commdx.com.
